MetaCap

AC Immune SA (ACIU) vs NervGen Pharma (NGEN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AC Immune SA (ACIU) has outperformed NervGen Pharma (NGEN) over the past year, losing 35.0% versus a loss of 35.0%. Over five years, NGEN leads with a -9.6% price change compared with -62.3% for ACIU. NervGen Pharma is the larger company by market cap ($198.6 million vs $193.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACIU-35.00%NGEN-35.04%
+118%+28%-62%
Nov 21, 20251 yearNov 20, 2026
ACIU-64.35%NGEN-16.85%
+177%+46%-85%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACIU versus NGEN key metrics
MetricACIUNGEN
Share price$1.95$1.85
Market cap$193.88M$198.55M
1-day change-8.45%-3.91%
YTD return-37.90%-67.05%
1-year return-35.00%-35.04%
5-year return-62.28%-9.56%
Forward P/E2.84—
EPS (TTM)$-0.44$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$3.90$6.30
52-week low$1.93$1.28
Distance from 52-week high-50.00%-70.71%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+331.28%+442.01%
Average volume198.81K621.66K
Shares outstanding99.43M107.62M
Employees909
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AC Immune SA

ACIU stock →

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees

About NervGen Pharma

NGEN stock →

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

ACIU vs NGEN FAQ

Which is bigger, AC Immune SA or NervGen Pharma?

NervGen Pharma (NGEN) is larger, with a market capitalization of $198.55M compared with $193.88M for AC Immune SA (ACIU).

Which stock has performed better over the past year, ACIU or NGEN?

ACIU returned -35.00% over the past 12 months, compared with -35.04% for NGEN (price return, excluding dividends). Past performance does not predict future results.

Are AC Immune SA and NervGen Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons